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Abstract: Antimicrobial stewardship programs (ASPs) are effective means to optimize prescribing
practices. They are under-utilized in the Middle East where many challenges exist for ASP implementation. We assessed the effectiveness of infectious disease physician-driven post-prescription review
and feedback as an ASP in Lebanon. This prospective cohort study was conducted over an 18-month
period in the medical, surgical, and intensive care units of a tertiary care hospital. It consisted of
three phases: the baseline, intervention, and follow-up. There was a washout period of two months
between each phase. Patients aged ≥16 years receiving 48 h of antibiotics were included. During the
intervention phase, the AMS team reviewed antimicrobial use within 72 h post-prescription and gave
alternate recommendations based on the guidelines for use. The acceptance of the recommendations
was measured at 72 h. The primary outcome of the study was days of therapy per 1000 study patient
days. A total of 328 patients were recruited in the baseline phase (August–October 2020), 467 patients in the intervention phase (January–June 2021), and 301 patients in the post-intervention phase
(September–December 2021). The total days of therapy decreased from 11.46 during the baseline
phase to 8.64 during the intervention phase (p < 0.001). Intervention acceptance occurred 88.5% of the
time. The infectious disease physician-driven implementation of an ASP was successful in reducing
antibiotic utilization in an acute care setting in Lebanon.
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1. Introduction
Antimicrobial resistance (AMR) is an urgent threat to global health; contributing to
over 8 million hospital stays, it costs healthcare systems over USD 20 billion [1] and is
anticipated to result in the death of 10 million people per year by 2050 [2,3]. AMR is a
unique challenge, particularly in areas of the Middle East where health services have been
severely impacted by conflict [4]. In these collapsed health systems, there may be a lack of
laboratories and other diagnostic tools amidst the unregulated use of antibiotics [4]. In one
observational study, multidrug-resistant organisms were frequently detected in water in
Lebanon, serving as a potential reservoir for the dissemination of resistant organisms [5].
Furthermore, conflict contributes to a shortage of healthcare providers, further worsening
the overall crisis [6]. The lack of overall data and surveillance of AMR in this region makes
it especially difficult to compare it with the rest of the world, thus limiting opportunities
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for intervention. More recently, barriers for the region were summarized and included
a need for the training of healthcare personnel and an increased laboratory capacity for
the surveillance of AMR as well as the development of antimicrobial stewardship (AMS)
guidelines [7].
The most important causes of AMR are inappropriate antimicrobial prescribing and
use [2]. Recognizing the urgency of this issue, various AMS programs (ASPs) have been
implemented to reduce AMR and promote proper prescribing practices. In order for ASPs to
be effective, significant infrastructural components must be present, including national and
institutional prescribing policies, healthy prescriber–pharmacist relationships, surveillance
and reviews of prescribing practices, and stakeholder buy-ins [8]. Institutions in the Middle
East are lacking in firm guidelines for proper antimicrobial use. One systematic review
identified 20 studies that described potential proactive interventions with impacts on the
de-escalation of antibiotics, discontinuation rates of restricted antibiotics, and length of
hospital stay, and that prospective audits and feedback were beneficial for the clinical
outcome [1]. Yet, it was also noted that cultural considerations in the Middle East such
as physician attitudes, the acceptance of collaborative practices, and the acceptance of
pharmacist recommendations may limit effectiveness [1].
The post-prescription review and feedback (PPRF) program has been shown to be
effective in the United States and in low- to middle-income countries, including Nepal and
India [9–11]. This method of ASP has not been demonstrated to be effective in the Middle
East and North Africa regions. This project evaluated the impact of a PPRF program at a
tertiary hospital in Lebanon.
2. Materials and Methods
2.1. Study Design and Setting
This prospective cohort study was carried out to determine the feasibility of the
implementation of an ASP. The study period consisted of 21 months from April 2020 to
December 2021, and was divided into 3 phases: the baseline (3 months), intervention
(6 months), and post-intervention (4 months). There was a washout period of 2 months
between each phase. The project was a collaboration between the Henry Ford Hospital
Division of Infectious Diseases (Detroit, MI, USA) and Notre Dame des Secours University
Hospital (Byblos, Lebanon). The Notre Dame des Secours University Hospital is a private,
not-for-profit tertiary care teaching hospital with 242 beds and covers a diverse population
of medical cases from a wide geographic area. For the present study, the PPRF program
was piloted in medicine, surgery, and intensive care unit wards.
In this institution, there was no integrated multidisciplinary AMS team. A team
was established to supervise and complete all phases of the project. The dedicated AMS
team was composed of an ID specialist, and infection prevention and control officers. The
institutional review boards of Notre Dame des Secours University Hospital and Henry
Ford Hospital approved the study. A waiver of consent was obtained due to the nature of
the study.
2.2. Identification of the Study Participants
Participants were selected from medical, surgical, and intensive care unit wards
and were managed by a primary treating team who remained the same throughout the
study. The inclusion criteria were that all patients were aged ≥16 years and had received
antibiotics for ≥48 h. The exclusion criteria were patients aged ≤16 years and on antibiotics
for ≤48 h. All medical and surgical specialties were included in the study and patients
fulfilling the eligibility criteria were recruited daily. The medical records were reviewed
and data were collected at each phase of the study, including the demographic data (age
and gender), comorbidity, infection type, antibiotic used, length of hospital stay, and total
antibiotic days.
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2.3. Design of the Phases and the Evaluation of Antimicrobial Use
The baseline phase involved 3 months of evaluation of antimicrobial therapy without
the provision of any recommendations. Meanwhile, continuous education was initiated
and included regional AMR data and the prevention and management of resistance as
well as the components and goals of the ASP, details regarding the PPRF implementation
within the institution, and a review of the medical guidelines. Sessions were delivered
to physicians in different specialties. Practice guidelines were prepared and supervised
by the ID specialist and sent to all physicians working at the institution. The guidelines
contained recommendations for an empiric therapy (given for early sepsis with an unclear
etiology) as well as a definitive therapy for common infectious syndromes, intravenous to
oral conversions, renal-adjusted dosing, and the duration of the antibiotic therapy. Due
to the COVID-19 pandemic, webinars were scheduled to educate the healthcare staff and
address questions regarding these topics.
The intervention phase occurred following a 2-month washout period. The phase
consisted of 6 months of intervention, during which the AMS team initiated a consultation
for all eligible patients. During the AMS consultation, the ID physician was responsible
for informing the primary treatment team of any recommendations about an antibiotic
change. Types of interventions included dose optimization, the escalation of therapy,
the de-escalation of therapy, route changes, drug discontinuation, the optimization of
administration modalities, and “other”. The final decision to act on the recommendations
was left to the primary team. The willingness to accept the intervention, type of primary
service, and reasons for not accepting the intervention were also recorded (“not convinced”,
“felt insecure”, or “needed a longer duration”). For this study, “not convinced” implied
that they were not convinced by the AMS team to accept the recommendation and “felt
insecure” implied a lack of confidence in changing antimicrobials.
The final (post-intervention) phase occurred after a 2-month washout period. It was
designed to re-assess antibiotic prescriptions in the same way as the baseline phase for a
period of 4 months to assess if the ASP could be sustained without an intervention. During
each period, AMS education continued via webinars, facility-based guidelines, and emails.
2.4. Outcome Measures
The primary outcome measure was the antimicrobial DOT at the baseline, intervention,
and post-intervention phases. In this study, patient antibiotic days included the day on
which the treatment with the antibiotic began through the stoppage of the drug or hospital
discharge. Additionally, information regarding the class/type of antibiotic utilized in each
phase and for what illness was also compared. The patient-specific outcome was the length
of hospital stay per phase.
At the time of the PPRF launch, an email was sent to all physicians within the hospital
introducing the ASP. A survey was prepared and sent by email to all 106 physicians in
the institution admitting patients to the 3 mentioned units to evaluate the qualitative data,
including the perceptions and attitudes regarding antibiotics, level of basic knowledge
about antibiotic prescriptions and resistance, and outcome data that could be used to
identify potential barriers and facilitators in the implementation and dissemination of
future ASPs.
2.5. Statistical Analysis
Continuous data were described using means and standard deviations whereas categorical data were described using counts and column percentages. Univariate two-group
comparisons were conducted using independent two-group t-tests for the continuous
variables and chi-squared tests for the categorical variables. Two Poisson regression models
were utilized to assess the magnitude and significance of the intervention phase on antibiotic days and hospitalization treatment days whilst adjusting for the confounders of age,
gender, and treatment indication category. The total DOT per 1000 study patient days (PDs)
was calculated at the baseline, intervention, and post-intervention periods for each antibi-
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otic. An ANOVA was used to compare the mean antibiotics per day between the phases.
The proportion of each variable was compared between the baseline and intervention time
points, then between the intervention and post-intervention time points, then between the
baseline and post-intervention periods using tests of proportion. These values were then
compared using proportion tests with a Bonferroni adjustment between the phases. The
statistical significance was set at p < 0.05. The analyses were performed using Epi Info-7
(Centers for Disease Control and Prevention, Atlanta, GA, USA) and SAS 9.4 (SAS Institute
Inc., Cary, NC, USA).
3. Results
3.1. Study Population
A total of 328 patients were recruited in the baseline phase (August–October 2020),
467 patients in the intervention phase (January–June 2021), and 301 patients in the postintervention phase (September–December 2021) (Table 1). There was an even distribution
of gender across the baseline and intervention, but significantly more females in the postintervention period (p = 0.045). The mean age of patients was 67.6 years in the baseline
group; patients were significantly younger in the intervention group compared with preintervention, which occurred in a COVID-19 surge (p = 0.002). In the baseline period,
compared with both the intervention and post-intervention periods, there were significantly
more patients with pulmonary comorbidities (32% vs. 6.2% vs. 6.9%, p < 0.001). There were
significantly more patients with a hepatic/gastrointestinal comorbidity in the intervention
and post-intervention periods when compared with the baseline period (1.5% vs. 4.9%
vs. 4.7%, p = 0.01). Oncologic and renal diseases were significantly more common in the
post-intervention period (17.8%, p = 0.001 and 14.5%, p = 0.002, respectively).
Table 1. Summary of demographic data and days of therapy.

Demographics

Gender, female
Mean age (SD)
Median LOS (SD)
Median duration of antibiotic course
Median duration of antibiotic
days/patient (SD)
Pulmonary
Cardiac
Vascular
Endocrine
Neurologic
Hepatic/GI
Heme/onc
Renal
Other

Pre-Intervention
(n = 328)

Intervention
(n = 467)

Post-Intervention
(n = 301)

p-Value
Phase 1 vs. 2
b Phase 1 vs. 3
c Phase 2 vs. 3

40.24% (132)
67.6 (16.7) Range 17–97
6.00 (6.7) Range 1–41
5.00 (6.27) Range 1–40

38.89 (182)
63.72 (17.65) Range 16–96
6.00 (4.8) Range 1–42
5.00 (4.26) Range 1–39

46.48% (99)
65.84 (17.4) Range 16–97
7.00 (5.1) Range 3–75
6.00 (5.01) Range 2–25

0.69 a , 0.05 b , 0.08 c
<0.01 a , 0.02 b , 0.10 c
<0.01
<0.01

8.00 (12.44) Range 1–118

7.00 (7.4) Range 1–63

8.0 (9.46) Range 1–63

32.01% (105)
51.83% (170)
3.05% (10)
35.98% (118)
5.79% (19)
1.52% (5)
9.15% (30)
7.01% (23)
6.71% (22)

6.21% (29)
52.68% (246)
1.93% (9)
39.4% (184)
7.49% (35)
4.93% (23)
14.99% (70)
8.57% (40)
16.9% (79)

6.9% (21)
48.7% (148)
2.6% (8)
35.5% (108)
4.6% (14)
3.9% (12)
17.8% (54)
14.47% (44)
19.1% (58)

a

<0.01
a,

<0.01 <0.01 b , 0.70 c
0.81 a , 0.43 b , 0.29 c
0.31 a , 0.74 b , 0.50 c
0.33 a , 0.90 b , 0.29 c
0.35 a , 0.50 b , 0.11 c
0.01 a , 0.06 b , 0.53 c
0.01 a , <0.01 b , 0.29 c
0.42 a , <0.01 b , 0.01 c
<0.01 a , <0.01 b , 0.43 c

3.2. Evaluation of Antimicrobial Use
The type of infection treated varied considerably between the phases. However, across
all 3 phases, the most common infection treated was pneumonia. In the intervention phase,
there was a significantly higher number of patients receiving an empirical treatment (17.5%
compared with 3.1% at the baseline, p < 0.001); this was also true for the post-intervention
phase (7.6%, p < 0.001). The number of patients treated for a gastrointestinal infection or
a urinary tract infection and receiving postoperative prophylaxis significantly decreased
in the intervention and post-intervention phases and was most significant between the
baseline and intervention phases (13.2% vs. 3.8%, p < 0.001; 25.1% vs. 13.5%, p < 0.001; and
11.1% vs. 4.1%, p < 0.001, respectively). Skin and soft tissue infections were significantly
more common in the post-intervention phase (11.1% vs. 2.6% in intervention, p < 0.004).
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In the intervention phase, which occurred during a COVID-19 surge, empiric therapies
(3.1% vs. 17.5%, p < 0.001) and “other” infections (9.45% vs. 31.8%, p < 0.001) significantly
increased (Table 2).
Table 2. Type of infection treated in each phase.

Treatment Indication

Pre-Intervention
(n = 326)

Intervention
(n = 467)

Post-Intervention
(n = 301)

p-Value
Phase 1 vs. 2
b Phase 1 vs. 3
c Phase 2 vs. 3

Empirical treatment
Pneumonia
Gastrointestinal
Sepsis
Urinary tract infection
Postoperative prophylaxis
Skin and tissue infection
Diabetic foot infection
Other

3.07% (10)
26.69% (87)
13.19% (43)
3.05% (10)
25.15% (82)
11.04% (36)
4.91% (16)
3.37% (11)
9.45% (31)

17.5% (82)
23.3% (109)
3.85% (18)
1.92% (9)
13.46% (63)
4.06% (19)
2.56% (12)
1.5% (7)
31.8% (149)

7.6% (23)
22% (67)
3.9% (12)
2.3% (7)
18.1% (55)
2.9% (9)
11.1% (34)
1.3% (4)
32.9% (100)

<0.001 a , 0.01 b , 0.001 c
0.276 a , 0.17 b 0.69 c
<0.001 a , <0.001 b 0.94 c
0.298 a , 0.55 b , 0.71 c
<0.001 a , 0.03 b , 0.08 c
0.001 a , 0.001 b , 0.42 c
0.0784 a , 0.004 b , <0.0001 c
0.080 a , 0.09 b , 0.83 c
<0.001 a , <0.001 b , 0.76 c

a

The choice of antimicrobial agent also significantly differed between the phases. There
was an increase in days of vancomycin use compared with the baseline (57.83 DOT/1000 PD
vs. 101.03, p < 0.01), with higher results in the post-intervention period compared with the
baseline (150.26, p < 0.01). There was a significant reduction in the use of carbapenems between the baseline and intervention periods (455.62 DOT/1000 PD vs. 322.75, p < 0.01) with
an increase in post-intervention prescribing in both phases (567.02 DOT/1000 PD, p < 0.01,
p < 0.01). Beta-lactam use increased during the intervention phase (139.23 DOT/1000 PD to
187.24, p < 0.01) and returned to similar levels during post-intervention (122.97 DOT/1000 PD,
p < 0.01) when compared with the intervention phase. In the post-intervention period,
an increase in cephalosporin and carbapenem use was noted when compared with the
baseline period; however, this did not reach a statistical significance. There was also a
significant increase in the duration of aminoglycoside use in the post-intervention period
when compared with the intervention period (4.6 vs. 2.9, p = 0.004) (Table 3).
Table 3. Antibiotic agent used in each phase.

DOT/1000 by Agent
Mean

Intravenous antibiotics
Oral antibiotics
Vancomycin
Linezolid
Trimethoprim-sulfamethoxazole
Doxycycline
Penicillin
Beta-lactam/BLI
Cephalosporin
Carbapenem
Metronidazole
Azithromycin
Clindamycin
Fluoroquinolone
Colistin
Aminoglycoside
Tigecycline
Other

Baseline
(n = 328, Patient
Days 2715)

Intervention
(n = 467, Patient
Days 3306)

Post-Intervention
(n = 301, Patient
Days 2529)

1317.86
1250.18
67.03
57.83
15.84
11.42
7
6.26
139.23
306.08
455.62
60.77
2.94
2.58
95.03
0
20.99
13.26
189.3

1205.08
1197.96
18.15
101.03
11.8
0
0
2.12
187.24
399.58
322.75
51.72
9.68
9.98
88.02
0
11.19
25.11
0

1296.56
1263.3
25.32
150.26
22.14
0
1.98
17
122.97
248.71
567.02
27.68
5.54
17
67.62
25.3
16.2
18.2
9.49

BLI: beta-lactamase inhibitor; SD: standard deviation.

p-Value
Phase 1 vs. 2
b Phase 1 vs. 3
c Phase 2 vs. 3
a

0.82
a,

<0.01 <0.01 b , 0.06 c
<0.01 a , <0.01 b , <0.01 c
0.53 a , 0.28 b , <0.01 c
<0.01 a , <0.01 b
<0.01 a , 0.02 b , 0.03 c
0.03 a , < 0.01 b , <0.01 c
<0.01 a , 0.25 b , <0.01 c
<0.01 a , <0.01 b , <0.01 c
<0.01 a , <0.01 b , <0.01 c
0.38 a , <0.01 b , <0.01 c
0.04 a , 0.42 b , 0.22 c
<0.01 a , <0.01 b , 0.06 c
1.000 a , <0.01 b , 0.01 c
<0.01 b , <0.01 c
0.01 a , 0.6 b , 0.29 c
<0.01 a , 0.45 b , 0.23 c
<0.01 a , <0.01 b , <0.01 c
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3.3. Intervention Acceptance
In the intervention phase, there were 467 interventions from the AMS team, which
were accepted 414 times (88.5%). The most commonly performed intervention was “other”
(234 (56.2%)), followed by drug discontinuation (108 (25.9%)). The escalation of therapy
and the de-escalation of therapy occurred 25 times, respectively (6.1%, respectively). Dose
optimization, route change, and administration modality optimization were less frequently
performed (17 (4%), 5 (1.2%), and 2 (0.5%), respectively). For the 54 occurrences where an
intervention was not accepted (11.5%), the reason for not accepting was most commonly
due to a report of being “not convinced” (41 (75.9%)). Feeling insecure and needing
a longer duration of therapy were less common reasons of not accepting (5 (9%) and
9 (16%), respectively). Among the types of interventions, the intervention that was most
commonly not accepted was drug discontinuation (24%). Among the treatment providers,
the primary service that did not accept an intervention the most frequently was surgery
(15.9%) compared with medicine (12.4%) and the intensive care unit (12%).
3.4. Clinical Outcomes
Despite the increase in antimicrobial prescriptions for “other” infections and empirical
therapies, the total days of antibiotic therapy decreased from 11.46 during the baseline
phase to 8.64 days during the intervention phase (p < 0.00001). In the post-intervention
phase, the total antibiotic days of therapy (DOT) was 10.9, and, although this number
was lower than in the baseline phase, the effect did not meet a statistical significance
(p = 0.57) (Table 1). After adjusting for age, sex, and treatment indication, members in the
pre-intervention phase were on antibiotics 29% longer (p < 0.001) and hospitalized 16%
longer (p < 0.001) than members in the intervention phase. After adjusting for age, sex, and
treatment indication, members in the pre-intervention phase were on antibiotics 6% longer
(p = 0.02) and hospitalized 3% longer (p = 0.33) than members in the post-intervention
phase.
Of the 106 physicians, 20 completed the post-intervention survey, which was a response rate of 18.8%. The majority of respondents (12 (60%)) were female and the median
age was 29.6 years old. Most respondents were practicing in the field of medicine (n = 14)
and had a median of 6 years since the completion of their highest education. Their perceptions on antibiotic prescribing and knowledge were then assessed. The majority of
respondents agreed or strongly agreed that inappropriate antibiotic prescribing put patients
at risk and that AMR was a problem in the hospital where they worked. The majority
of respondents felt that they had received inadequate training in antibiotic prescribing
and that there was a need to increase the education of healthcare providers on AMR and
antimicrobial prescribing. The majority of respondents felt that the PPRF would increase
AMS without being disruptive to their work. Most respondents noted that they had
never prescribed antibiotics because a patient insisted on it or to improve relationships
with their patients. The most useful means of increasing antimicrobial prescribing education were felt to be short written guidelines, seminars, and summary written materials
(Supplementary Tables S1–S4).
4. Discussion
4.1. PPRF Programs
This study was the first in Lebanon to examine the impact of the implementation
of an infectious disease (ID) physician-driven PPRF strategy of AMS. In the intervention
period, there was a significant reduction in DOT, type of illness treated, and types of
antimicrobials in use and an indirect decrease in the length of hospital stay. The PPRF
was noted to have many advantages. The program engaged the treating physicians with
medical discussions, promoting an opportunity for education within medical teams. It
also had a positive impact on collaborative clinical decision-making regarding antibiotic
therapy modifications or discontinuations. Studies have shown that PPRFs build trust and
rapport between treatment teams [11] with an associated decrease in DOT [12]. In addition,
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there is an opportunity for the AMS team to evaluate the barriers and enablers that can
be used to modify the ASP [13]. At this institution, the PPRF was shown to be effective
by not only decreasing the total DOT, but also by reducing the use of broad-spectrum
antimicrobials such as carbapenems and beta-lactam/beta-lactamase inhibitors. The ASP
had an indirect impact on the length of hospital stay of the patients, which was shorter in
the intervention phase after adjusting for age, sex, and the treatment indication. Given that
COVID-19 pandemic waves occurred in that time period, this could have been a bias that
was not accounted for. However, this reduced length of hospital stay as a result of the ASP
has also been noted in other studies [14].
Notably, the acceptance of the AMS team recommendations was 88%, which was
higher than in prior studies that typically noted an acceptance rate of 60–70% [11,15,16]. We
believed that the type of patients admitted (the majority was pneumonia, particularly given
the COVID-19 surge in the intervention phase) and the use of verbal feedback and discussions as well as the continued stream of educational materials throughout the three phases
of the study may have had an impact on the acceptance of recommendations. Additionally,
the intervention was ID physician-led rather than pharmacist-led, as prior studies in the
Middle East have noted less acceptance from pharmacists [15]. The most frequent reason for
not accepting recommendations was the feeling of being “not convinced”, which implied
that there may be further work to be undertaken with further education on antibiotics with
teams. Importantly, it is worth noting that feeling “not convinced” may actually relate
to a need for behavioral change, with less reliance on personal knowledge or experience
and more reliance on guidelines and formal policy [16,17]. Acceptance rates in this study
were notably lower among surgical specialties, which was consistent with a prior similar
study in Nepal [9]. Management guidelines across different specialties could strengthen the
treating of the certainty of the clinical decisions of physicians, particularly when there are
unified treatment algorithms according to local epidemiology data [18]. Furthermore, the
integration of rapid diagnostic tools and the strengthening of laboratory capacities could
help clinicians in their decision-making when empirically treating complicated cases [19].
4.2. Physician Attitudes
This study took into account the attitudes toward the ASP of the treating physicians at
the study hospital. Although the number of participants in the survey was low, there was a
general consensus among the participants about perceptions and barriers toward a PPRF.
Additionally, the survey responses alerted a potential lack of confidence in knowledge
about antibiotic prescribing and issues with insufficient training. The need for regular
educational programs on prescribing has been cited in other ASPs [20]. Potential options for
educational programs could include workshops and guidelines; prescribers tend to prefer
guidelines locally developed rather than nationally developed [16]. Continued medical
education should include seminars and modules with case studies and these educational
programs should be routinely audited to ensure they can be integrated into prescriber
schedules [9]. Importantly, three participants in the survey felt that the PPRF could be
disruptive to the patient treatment. A recent study, also in Lebanon, evaluated physician
attitudes toward the core elements of an ASP and found that 34% of participants felt that
the ASP could affect physician autonomy [21]. Less restrictive stewardship programs,
including PPRFs and antibiotic rounds, are possible ways to circumvent this issue, which
may stem from cultural aspects of medicine in the region [15,22].
4.3. Impact of the Timeline on the Study
The study timeline directly coincided with COVID-19 surges that impacted on each
phase. Two-month washouts were performed due to delays from the impact of COVID-19
and the economic collapse. Due to the increased hospitalization rate of COVID-19 patients,
many were admitted to floors that were part of the intervention phase of the study and thus
included in the PPRF. Admitted COVID-19 patients were frequently empirically treated
for pneumonia, providing a unique opportunity for the AMS team to intervene, given
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prior studies that showed that although more than 90% of hospitalized COVID-19 patients
received empiric antibiotics, only 15% were documented to have a secondary bacterial
infection [23,24]. The rates were lower in other observational reports, increasing the hospital
stay from 3.2% up to 6.1% [25]. However, it was unclear whether the COVID-19 surges
in this study also led to greater antibiotic de-escalation as well as more readily acceptable
interventions from our AMS team as a result of the known (viral-etiology) pandemic.
The economic collapse of Lebanon—which began in October 2019, but has significantly progressed since then (6)—directly impacted on the post-intervention phase of this
study. During the post-intervention phase, there was a severe shortage of many antibiotics.
Antibiotics were thus selected based on availability and not per empiric or treatment guidelines. This was clearly noted in our results where the use of carbapenems, cephalosporins,
aminoglycosides, and colistin were higher in the post-intervention period. During this
phase, an emphasis on the duration of therapy rather than the antibiotic agent choice was
placed within stewardship education.
4.4. Strengths and Limitations
Separate from the direct impact of the economic collapse and COVID-19, there were
other limitations to our study. Logistic challenges in place resulted in shortages of providers,
which may have affected the ease of education of the treatment teams. Additionally, we
did not take into account the severity of disease, mortality/survival benefit, or types of
multidrug-resistant organisms treated, which might have impacted on the acceptance rate
of the interventions, the type of interventions, and the type of antibiotics used. Finally, due
to delays, the study was limited to an 18-month period, making assessments of changes
to the AMR and susceptibility patterns impossible. This was also compounded by factors
outside the control of a hospital program such as outpatient antimicrobials and antibiotic
use in agricultural feeds.
A number of strengths exist in this study. First, the large number of patients recruited
helped power the study appropriately for the analysis. Furthermore, the interrupted time
series with washout periods between the phases reduced any bias that may have been
associated with recent and direct education provided by the AMS team. Finally, the interventions were made with active dialogue and constant interaction with the treatment teams.
This may have accounted for the increased acceptance of the recommendations compared
with those PPRFs that use electronic medical record alerts. Using multidisciplinary collaboration and education were essential components of the ASP. Although labor-intensive, the
overall primary outcome was clear and the secondary impact on the cost analysis given the
reduction in the length of hospital stay is a potential direction for future studies.
5. Conclusions
Multifaceted approaches are needed to combat AMR across the Middle East. AMS
education and strategies, including PPRFs, are useful methods to reduce DOT.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/antibiotics11050642/s1, Table S1: Physician survey responses—
basic demographics.; Table S2: Physician survey responses on perceptions, knowledge, systemic
failures and barriers, and attitudes towards a post-prescription review and feedback program (n = 20).;
Table S3: Physician survey responses on supports and rewards for antimicrobial stewardship.;
Table S4: Physician survey responses on useful means of increasing healthcare provider knowledge
about antimicrobial resistance and treatment practices.
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